Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: An evidence-based pharmacotherapeutic case report

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 1, 2003, Pages 69-72

  Boutilier, A S W ^a   Gardner, David M ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; GABAPENTIN; IBUPROFEN; KETOROLAC; PARACETAMOL; PAROXETINE; RIZATRIPTAN; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; ZOLMITRIPTAN;

ARTICLE; CLINICAL TRIAL; DATA BASE; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG TOLERABILITY; EPILEPTIC AURA; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; IRRITABLE COLON; KIDNEY FAILURE; LIPOPHILICITY; MIGRAINE; NEUROLOGIC DISEASE; SEROTONIN SYNDROME;

DEPRESSION; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLIDINONES; PAROXETINE; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; TRYPTAMINES;

EID: 0037293246     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00453.x     Document Type: Article

References (17)

1. Jhee SJ, Shiovitz T, Crawford AW, Cutler NR. (2001) Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents. Clinical Pharmacokinetics, 40, 189-205.
2. Evans RW, Lipton RB. (2001) Topics in migraine management: a survey of headache specialists highlights some controversies. Neurologic Clinics, 19, 1-21.
3. Eadie MJ. (2001) Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs, 16, 105-118.
4. Product Monograph. (2002) Zomig (zolmitriptan). Mississauga, Ontario: AstraZeneca Canada Inc.
5. Leung M, Ong M. (1995) Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors. Headache, 35, 488-489.
6. Tepper SJ. (2001) Safety and rational use of the triptans. Headache, 85, 959-970.
7. Joffe RT, Sokolov STH. (1997) Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatrica Scandinavica, 95, 551-552.
8. Breslau N, Merikangas K, Bowden CL. (1994) Comorbidity of migraine and major affective disorders. Neurology, 44 (Suppl. 7), 17-22.
9. Mitsikostas DD, Thomas AM. (1999) Comorbidity of headache and depressive disorders. Cephalalgia, 19, 211-217.
10. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KM. (2000) Headache and major depression: is the association specific to migraine? Neurology, 54, 308-313.
11. Smith DA, Cleary EW, Watkins S, Huffman CS, Polvino WJ. (1998) Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers. International Journal of Clinical Pharmacological Therapy, 36, 301-305.
12. Putnam GP, O'Quinn S, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW. (1999) Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia, 19, 668-675.
13. Goldberg MR, Lowry RC, Musson DG et al. (1999) Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. Journal of Clinical Pharmacology, 39, 192-199.
14. Deleu D, Hanssens Y. (2000) Current and emerging second-generation triptans in acute migraine therapy: a comparative review. Journal of Clinical Pharmacology, 40, 687-700.
15. Bezchlibnyk-Butler KZ, Jeffries JJ (eds) (2001) Clinical handbook of psychotropic drugs. Toronto: Hogrefe and Huber Publishers.
16. Product Monograph. (2000) Imitrex (sumatriptan). Mississauga, Ontario: Glaxo-SmithKline.
17. Product Monograph. (2002) Maxalt (rizatriptan). Kirkland, Quebec: Merck Frosst Canada & Co.